# Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

> **NCT02669121** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 4748 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** NoV Placebo-matching Saline
- **BIOLOGICAL:** NoV GI.1/GII.4 Bivalent VLP Vaccine

## Key facts

- **NCT ID:** NCT02669121
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-14
- **Primary completion:** 2018-06-16
- **Final completion:** 2018-06-16
- **Target enrollment:** 4748 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669121, "Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02669121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*